For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Afamelanotide and NB-UVB (Pooled Analysis) | The study design was modified from a randomised controlled (Afamelanotide plus NB-UVB versus placebo plus NB-UVB) to an open label study (afamelanotide plus NB-UVB). A pooled analysis of all patients who received afamelanotide plus NB-UVB was undertaken and the results are presented. | 0 | None | 0 | 18 | 4 | 18 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Fatigue | None | General disorders | None | View |
| Glomerular filtration rate decreased | None | Investigations | None | View |
| Urinary casts | None | Investigations | None | View |
| Lethargy | None | Nervous system disorders | None | View |
| Nail pigmentation | None | Skin and subcutaneous tissue disorders | None | View |